AI Continues to Push the Field of Radiation Oncology ForwardMarch 19th 2023
In an interview with Targeted Oncology, Matthew Manning, MD, FASTRO, discussed the many radiation oncology tasks that have been improved with AI and its prospective utility in cancer diagnosis and treatment decisions.
Trial to Assess PRT2527 Plus Zanubrutinib for Hematologic MalignanciesMarch 18th 2023
The combination of CDK9 plus BTK inhibition has already demonstrated synergistic clinical efficacy vs BTK inhibition alone. Now, a clinical trial collaboration will evaluate PRT2527 and zanubrutinib for patients with hematologic malignancies.
Clinicians Must Address Unusual AEs of BRAF/MEK Inhibition for BRAF-Mutated NSCLCMarch 17th 2023
A case report published in The Journal of the National Comprehensive Cancer Center highlights the importance of being mindful of unusual adverse events associated with BRAF/MEK inhibition for patients with BRAF-mutated non–small cell lung cancer.
Enzalutamide/Leuprolide Extends MFS in nmHSPC With High-Risk Bochemical RecurrenceMarch 17th 2023
The phase 3 EMBARK trial of enzalutamide plus leuprolide is the first to elicit a statistically significant improvement in metastasis-free survival in non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade GliomaMarch 16th 2023
Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.
BCMA Therapies Changing Treatment in Relapsed/Refractory Multiple MyelomaMarch 16th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Rafael Fonseca, MD, discusses how targeting patients with relapsed/refractory multiple myeloma with B-cell maturation antigens like teclistamab is changing the treatment landscape.
Hitting New Targets in Metastatic Prostate CancerMarch 16th 2023
In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy.
Molecular Targets Making Headway in Pediatric Thyroid Cancer ResearchMarch 16th 2023
In an interview with Targeted Oncology, Aime T. Franco, PhD, discussed the molecular landscape of pediatric patients with thyroid cancer and the presentation she gave at the 91st Annual Meeting of the American Thyroid Association.
Ajani Discusses Immune Checkpoint Inhibition in HER2-Negative Upper GI CancerMarch 16th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Jaffer A. Ajani, MD, discussed the trials investigating the use of immune checkpoint inhibitors in patients with upper gastrointestinal cancers.
Lenvatinib/Pembrolizumab Shows Survival Benefit in Endometrial CancerMarch 15th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Thomas J. Herzog, MD, discussed the results of the KEYNOTE-775 trial of lenvatinib plus pembrolizumab versus chemotherapy in patients with advanced endometrial cancer.
Enzalutamide Plus ADT Improves Time to PSA Progression in mHSPCMarch 15th 2023
Investigators from the China ARCHES trial of enzalutamide plus androgen deprivation therapy announced that it had met its primary end point in Chinese patients with metastatic hormone-sensitive prostate cancer.
FDA Awards Orphan Drug Designation to EP0042 for AML TreatmentMarch 15th 2023
Preclinical and phase 1/2a data evaluating the safety and tolerability of EP0042 in patients with relapsed or refractory acute myeloid leukemia has led the FDA to grant an orphan drug designation to the agent.
ELAINE-3 Study of Lasofoxifene Initiates for ESR1-Mutated ER+/HER2- Breast CancerMarch 15th 2023
Promising findings from the phase 2 ELAINE-1 and ELAINE-2 trials have led to the start of a phase 3 study where investigators will evaluate lasofoxifene and abemaciclib as a treatment for patients with ER-positive/HER2-negative breast cancer and an ESR1 mutation.
Roundtable Discussion: Geynisman Looks at the Latest Treatments in Metastatic Hormone-Sensitive Prostate CancerMarch 15th 2023
During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel Geynisman, MD, discussed with participants the choice of hormonal therapy for metastatic prostate cancer.
Multiple Myeloma Awareness Month: Advancing The Understanding of Targeted Therapies RoleMarch 14th 2023
Multiple Myeloma expert Santhosh K Sadavish MD, discusses the importance of targeted therapies for these patients and how CAR T-cell therapy has changed the outcomes of patients who relapse after multiple lines of therapy.